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ARTICLE
Whole-Genome Sequencing Coupled to Imputation
Discovers Genetic Signals for Anthropometric Traits
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Lorraine Southam,1,19 Beate St Pourcain,2,23 Michela Traglia,21 Katerina Trajanoska,13,16
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Deep sequence-based imputation can enhance the discovery power of genome-wide association studies by assessing previously unex-
plored variation across the common- and low-frequency spectra. We applied a hybrid whole-genome sequencing (WGS) and deep impu-
tation approach to examine the broader allelic architecture of 12 anthropometric traits associated with height, body mass, and fat
distribution in up to 267,616 individuals. We report 106 genome-wide significant signals that have not been previously identified,
including 9 low-frequency variants pointing to functional candidates. Of the 106 signals, 6 are in genomic regions that have not
been implicated with related traits before, 28 are independent signals at previously reported regions, and 72 represent previously
reported signals for a different anthropometric trait. 71% of signals reside within genes and fine mapping resolves 23 signals to one
or two likely causal variants. We confirm genetic overlap between human monogenic and polygenic anthropometric traits and find
signal enrichment in cis expressionQTLs in relevant tissues. Our results highlight the potential ofWGS strategies to enhance biologically
relevant discoveries across the frequency spectrum.
Introduction
The escalating global epidemic of overweight and obesity
can be ascribed to a complex interplay between environ-
mental and genetic factors. Body size, shape, and composi-
tion are anthropometric measures correlated with obesity
and patterns of fat deposition and are associated with
important metabolic health outcomes.1–3 Large-scale
genome-wide association studies (GWASs) for body mass
index (BMI), waist to hip ratio, and height have to date
focused on the role of common-frequency variants and
have unveiled numerous associations that explain a
modest proportion of trait variance;4–6 the role of low-fre-
quency variants has not been systematically explored
across the entire genome.
The application of whole-genome sequencing (WGS) at
a population scale and generation of high performance
imputation reference panels allows GWASs to systemati-
cally evaluate variation across the low- and common-
frequency minor allele frequency (MAF) spectra. Here, we
assessed the contribution of 15,844,966 sequence variants
to 12 anthropometric traits of medical relevance using
a hybrid approach of cohort-wide low-depth WGS7 and
imputation based on a sequence-based reference panel
comprising 9,746 haplotypes8 in a discovery set of
57,129 individuals (stage 1, Table S1). We followed up
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suggestive association signals at p % 105 in 210,823
individuals (stage 2, Table S1) of European descent and
identify 106 previously unreported signals for anthropo-
metric traits.
Material and Methods
Sequence Data Production
Low-read depth (73) WGS was performed in two UK cohorts,
the St Thomas’ Twin Registry9 (TwinsUK; n ¼ 1,990) and the
Avon Longitudinal Study of Parents and Children10 (ALSPAC;
n ¼ 2,040) as part of the UK10K project.7 Methods for the gener-
ation of these data are described in detail in Walter et al.7 and
Huang et al.8 In brief, low-coverage WGS was performed at both
the Wellcome Trust Sanger Institute and the Beijing Genomics
Institute. Sequencing reads that failed QC were removed and the
rest were aligned to the GRCh37 human reference. Further pro-
cessing to improve SNP and INDEL calling included realignment
around known indels, base quality score recalibration, addition
of BAQ tags, merging, and duplicate marking using GATK, Picard,
and samtools. SNPs and indels were called using samtools/bcftools
by pooling the alignments from 3,910 individual low-coverage
BAM files. All-samples and all-sites genotype likelihood files (bcf)
were created with samtools mpileup. Variants were then called
using bcftools to produce a VCF file.
After post-calling filtering, variant quality score recalibration
(VQSR) filtering was used to filter sites. VQSLOD scores are cali-
brated by the number of truth sites retained when sites with a
VQSLOD score below a given threshold are filtered out. For SNPs
and INDELs, a truth sensitivity of 99.5% and 97% was selected,
respectively. Sites that did not fail a number of further filters
(DP, MQ, AC, AN, LowQual, MinVQSLOD, BaseQRankSum, Dels,
FS, HRun, HaplotypeScore, InbreedingCoeff, MQ0, MQRankSum,
QD, ReadPosRankSum) were marked as PASS and brought forward
to the genotype refinement stage.
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Low-quality samples were identified by comparing the samples
to their GWAS genotypes using 20,000 sites on chromosome
20. Comparing the raw genotype calls to existing GWAS data, a to-
tal of 112 samples were removed for one or more of the following
causes: (1) high overall discordance to SNP array data, (2) hetero-
zygosity rate > 3 standard deviations (SD) from population
mean, (3) no SNP array data available for that sample, or (4) sam-
ple below 43mean coverage. Overall, 3,798 samples were brought
forward to the genotype refinement step.
Missing and low-confidence genotypes in the filtered VCFs were
filtered out through an imputation procedure with BEAGLE. Addi-
tional sample-level QC steps were carried out on refined geno-
types, leading to the exclusion of additional 17 samples for one
or more of the following causes: (1) non-reference discordance
with GWAS SNP data > 5%, (2) contamination identified by mul-
tiple relations (>25 to other samples with IBS> 0.125), or (3) failed
sex check. A final set of 3,781 samples (1,854 TwinsUK and 1,927
ALSPAC) in VCF files were submitted to the European Genome-
phenome Archive (EGA).
Cohort Descriptions
We consider 12 anthropometric traits: BMI, weight, height, waist
circumference, hip circumference, waist to hip ratio, total fat
mass, total lean mass, and trunk fat mass. Waist circumference,
hip circumference, and waist to hip ratio were also adjusted for
BMI. Our discovery stage consisted of 3WGS and 20GWAS datasets
genotyped on a variety of genotyping platforms (Table S2,
Figure S1). The WGS sets are from two UK cohorts, TwinsUK9
(EGAS00001000108) and ALSPAC10 (EGAS00001000090) as part
of the UK10K project,7 and from a Finnish cohort.11 Each of the
20 GWAS datasets was imputed on the combined UK10K and
1000 Genomes Project imputation panel (EGAS00001000713),
comprised of 4,873 WGSed individuals.8 The imputation of GWAS
data was conducted as follows. Raw data were obtained genome-
wide from each individual study, having undergone study-specific
quality control. The data were prephased with SHAPEIT v.2 and
the phased genotypes were then imputed to the combined UK10K
and 1000Genomes Project haplotype reference panel.8 Imputation
was carried out with IMPUTE v.2 with standard settings.12 In total,
GWAS data contributed up to 52,339 individuals of European
ancestry (UK, Italy, Greece, Germany, the Netherlands) (Tables S1
and S2). Therefore, our discovery phase included up to 57,129 indi-
viduals from23 cohorts of European origin.We followed up the top
signals de novo and in silico. Follow-up through de novo genotyp-
ing was sought in up to 37,851 UK13 and Danish samples14 using
Sequenom genotyping (Supplemental Data). In silico follow-up
was sought in up to 175,318 Europeans, the majority of whom
were imputed on the combined UK10K and 1000 Genomes Project
panel (Figure S1; Table S2). Descriptions of each of the cohorts are
given in the Supplemental Data.
Datasets Used for mQTL and eQTL Analyses
ARIES Data
The Accessible Resource for Integrative Epigenomic Studies
(ARIES) dataset represents genome-wide DNA methylation levels
on ALSPAC samples selected from 1,018 mother-child pairs at
three time points in children and two time points in their mothers
from cord blood drawn from the umbilical cord upon delivery or
peripheral blood15 using different cell types. The DNA methyl-
ation data were corrected for cellular heterogeneity (Supplemental
Data).
MuTHER-ALSPAC Data
TheUK10KMuTHER-ALSPACgene expressiondataset is comprised
of the subset ofUK10K individualswithmicroarray expressionpro-
files available from the TwinsUK MuTHER study16 and ALSPAC
expression study.17 Complete details can be found in Grundberg
et al.16 and Bryois et al.17 Both datasets were profiled on the same
Illumina HT12v3 array in the same facility within the same year.
Expression data were available for 823 lymphoblastoid cell lines
(LCL) (394 TwinsUK/MuTHER and 429 ALSPAC) and 2 primary
tissues in MuTHER/TwinsUK only (391 subcutaneous fat and 367
skin). All individuals were unrelated.
Phenotype Preparation Protocol
A standardized protocol for preparation of phenotypes was applied
to each cohort, as follows. Female and male participants were
divided into separate groups and transformations were under-
taken in a sex-specific manner. Outliers greater than 5 SD were
manually checked for data entry errors. Outliers greater than 3,
4, or 5 SD (depending on trait and cohort) from the mean were
removed and raw phenotypes were then transformed to obtain a
normal distribution using an inverse normal transformation. Sub-
sequently, the transformed traits were regressed on covariates and
the resulting residuals were standardized to have amean of 0 and a
SD of 1. Females and males were standardized separately before
being combined. Covariates (age and age2) were fitted as fixed ef-
fects. The DXA traits were further adjusted for height, whereas
waist circumference, hip circumference, and waist to hip ratio
were also adjusted for BMI. Analyses of all anthropometric traits
in GoT2D were performed with similar methodology to previous
publications by the GIANT Consortium. Within each study,
height was first adjusted for age and sex, as well as relevant
study-specific covariates such as principal components in a linear
regression model, and residuals were standardized. Similarly, all
obesity measures (waist circumference, hip circumference, and
waist to hip ratio) were adjusted for age, age2, sex, and study-spe-
cific covariates in linear regression, and the residuals were inverse
normalized. Information on trait measurements and units is sum-
marized in Table S2.
Single-Variant Tests
Assuming an additive genetic model, we used the likelihood ratio
test within a linear regression framework to model relationships
between standardized traits, residualized for relevant covariates,
and genetic variants. To account for the genotype uncertainty
that might arise from sequencing and imputation, we used geno-
type dosages, where each genotype was expressed on a quantita-
tive scale between [0:2] (using in SNPTEST18 the function -method
expected). Cohorts that contained related samples were analyzed
using GEMMA19 or EMMAX,20 standard linear mixed models
that control for family and cryptic relatedness (Table S2). Only
variants with MAFR 0.1%, minor allele count (MAC)R 4, impu-
tation quality score R 0.4 (Figure S2), and Hardy-Weinberg equi-
librium (HWE) pR 106 were analyzed.
Meta-analysis Strategy
Summary statistics from individual studies (filtered for HWE,
imputation quality score, MAC, and MAF) were combined
using fixed-effect inverse variance meta-analysis implemented
in METAL21 software package. We discarded any variants whose
signal was from a single cohort and also any variants that were
not successfully analyzed in any of the four ALSPAC and TwinsUK
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cohorts. None of the traits showed evidence of inflation due to
population stratification (genomic control inflation factors esti-
mated close 1; Figures S3–S14). The variance explained by each
SNP was calculated using the weighted effect allele frequency (f)
and beta (b) from the overall meta-analysis using the formula b2
(1  f)2f.
Clumping of Single Point Summary Statistics
We next applied a clumping procedure to represent each signal
from the association analysis as a clump of correlated variants.
This is achieved by assigning sets of variants to discrete LD bins
if their pairwise LD is r2 R 0.2 and if they are within 500 kb. For
each LD bin, the variant with the greatest evidence for association
with the trait in question was considered as the representative or
index variant for that locus.
Annotation of Index Variants for Previously
Reported Loci
A list of previously identified, GWAS-significant (p % 5 3 108)
anthropometric and obesity signals were collected from the
NHGRI-EBI GWAS catalog22 (accessed 4 March 2015, version
1.0). In addition to the GWAS catalog, our list contained signals
reported in the most recent anthropometric studies published by
the GIANT consortium.4–6 From these results, any signal reaching
genome-wide significance, either in the sex-specific or in sex-com-
bined analyses, was included in our positive control list with
the lowest reported p value. The total fat mass variants that we
regard as ‘‘known’’ are the total fat percentage variants reported
previously23,24 while the total lean mass variants reported in the
literature are for lean body mass.25 During the course of the study,
we updated our positive control list using the GWAS catalog and
by manual curation of all associations reported in the literature
reaching the same genome-wide significance cutoff.
Conditional Analysis
Conditional single-variant association analyses were carried out to
investigate statistical independence between index variants from
the clumping procedure and previously reported variants. Associ-
ations of SNPs with the respective quantitative trait were condi-
tioned on all previously reported variants within 1Mb of the index
variant. The conditional analysis was performed independently
for each discovery phase cohort for which we had access to the
raw genotypes (17 out of a total 23 cohorts) and a meta-analysis
was conducted. A variant was considered independent if it had
a conditional p value % 105 or a p value difference between
conditional and unconditional analysis of less than 2 orders of
magnitude. Variants were classified as known (denoting either a
previously reported variant, or a variant for which the association
signal disappears after conditioning on a previously reported lo-
cus) or newly identified (denoting a variant that is conditionally
independent of previously reported loci).
Genome-wide Significance Threshold
We consider p% 53 108 as genome-wide significant. To account
for testing of multiple phenotypes, we used the biggest cohort
with all phenotypes available (ALSPAC) and the eigenvalues of
the correlation matrix of the 12 anthropometric traits tested26 to
calculate the effective number of independent phenotypes as
4.482. This yields a Bonferroni-corrected threshold that controls
the FWER at 5% as 0.05/4.482. We used this threshold, as well as
a 5% false discovery rate (FDR), for enrichment of association
signal in discovery andmonogenic and syndromic disorder-associ-
ated genes.
Fine Mapping
For both newly identified (Tables 1, 2, and S3) and previously re-
ported (those with p % 5 3 108 in Table S4) variants, we con-
structed regions for fine mapping, by taking a window of at least
0.1 centimorgans (HapMap estimates following previous sugges-
tions27) either side of the variant. The region was extended to
the furthest variant with r2 > 0.1 with the index variant within
a 1 Mb window. For each region we implemented the Bayesian
fine-mapping method CAVIARBF,28 which uses association sum-
mary statistics and correlations among variants to calculate Bayes’
Table 1. Genome-wide Significant Associations at Newly Identified Loci
SNP Trait Chr:position
Nearest
Gene
Effect/Other
Allele
Stage 1
Frequency
(Effect
Allele) Beta (SE) p Value n I2 Phet
Low-Frequency or Rare
rs202238847 height 3: 49,263,637 CCDC36 C/CT 0.021 0.1091 (0.0233) 2.83 3 106 51,309 26.8 0.132
Common
rs1264622 height 6: 30,256,936 HLA-L/HCG17/
HCG18
T/C 0.190 0.0455 (0.0087) 1.76 3 107 50,372 13.0 0.296
rs11042397 hip 11: 9,524,255 ZNF143 T/C 0.056 0.0763 (0.0150) 3.56 3 107 45,588 2.3 0.429
rs13213884 height 6: 141,665,522 RP11-63E9.1 T/C 0.247 0.0419 (0.0074) 1.57 3 108 51,309 49.5 0.007
rs12424892 height 12: 132,623,389 DDX51 C/G 0.153 0.0457 (0.0095) 1.60 3 106 44,180 0.0 0.907
rs35863206 height 11: 101,055,183 RP11-788M5.4 C/CAG 0.222 0.0384 (0.0082) 2.77 3 106 45,588 21.8 0.190
SNP positions are reported according to build 37 and their alleles are coded based on the positive strand. The reported gene is the closest in physical distance.
Association p values are based on the inverse-variance weighted meta-analysis model (fixed effects). Effect sizes are measured in standard deviation units. Abbre-
viations are as follows: BMI, body mass index; SNP, single-nucleotide polymorphism; Beta, effect size; SE, standard error; n, sample size; I2, measure of hetero-
geneity (based on Cochran’s Q-test for heterogeneity) that indicates the percentage of variance in a meta-analysis that is attributable to study heterogeneity;
Phet, p value assessing evidence of heterogeneity as reported by METAL.
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factors and posterior probabilities of each variant being causal. We
assumed a single causal variant in each region and calculated 95%
credible sets.
To inform the prediction of causal variants using functional pre-
diction information, we also applied a fine-mapping method that
assigns a relative ‘‘probability of regulatory function’’ (PRF) score
among candidate causal variants, reweighting association statistics
based on epigenomic annotations. In brief, we collected a set of
70 genomic and epigenomic annotations, primarily Gencode
(v.19) gene annotations, FANTOM transcription start sites and
enhancers,29,30 Roadmap Epigenomics histone marks, DNase
hypersensitivity, and ChromHMM genome segmentations for the
lymphoblastoid cell line epigenome (GM12878).31,32 We used
fgwas33 to train a Bayesian hierarchical model to compute enrich-
ment of eQTLs in these annotations based on summary statistics
from the Geuvadis RNA-sequencing project.34 We used forward
stepwise selection followed by cross-validation to arrive at a com-
bined model with 37 annotations and their associated enrich-
ments. The respective annotations from119 Roadmap epigenomes
were used to compute PRF scores for each GWAS variant in each of
the 119 epigenomes. At each locus we selected the top four epige-
nomes based on the maximum regulatory score among variants
in the 95% credible set and examined the regulatory annotations
for variants in the credible set (Table S5, Figure S15). We also pro-
duced Genomic Evolutionary Rate Profiling (GERP) scores35,36 as
a measure of cross-species conservation of the sequences around
each identified association (Figure S16).
Genetic Correlation
To investigate the genetic correlation between the 12 anthropo-
metric traits studied here, we ran the LD Score37 method that
uses genome-wide summary statistics (independent of p value
thresholds) and LD estimates between variants while accounting
for sample overlap. We used summary statistics from our discov-
ery phase and LD Score restricts analyses to common variants
to avoid biases due to inherent model assumptions (Figure 1,
Table S6).
Enrichment of Association Signal
To evaluate enrichment of association signal in the meta-analysis,
we used the binomial test to determine whether the observed
number of variants with p value % 105 is higher than expected
by chance. We performed this test on all independent variants
(r2 < 0.2) present in the meta-analysis results and also after
excluding any previously identified variants (stringently defined
as all variants within 1 Mb window centered around previously re-
ported variants) (Figure S17).We also tested for enrichment within
different MAF categories (0.1% % MAF % 1%, 1% < MAF % 5%,
and MAF > 5%) (Figure S18).
To identify approximately independent variants, we used a
greedy selection strategy that processed variants sorted by their as-
sociation p value.We first retained the variant with the greatest ev-
idence of association and then filtered out any other variants
linked to it at an r2 threshold of 0.2 (calculated from the combined
ALSPAC and TwinsUK WGS data using the PLINK software38) and
then retained the next most strongly associated variant that has
not yet been filtered and repeat this process until there are no
further unfiltered variants remaining.
Enrichment of Association Signal in Monogenic and
Syndromic Genes Associated with Obesity, Height, and
Lipodystrophy
We examined whether the meta-analysis association signals clus-
ter near biologically relevant genes, specifically (1) genes mutated
in human syndromes characterized by abnormal skeletal growth,
(2) genes whose mutations lead to known human obesity-associ-
ated genetic disorders and syndromes, and (3) Mendelian lipodys-
trophy-associated genes. To this end, we used 241 abnormal
skeletal/growth-associated genes identified by Lango Allen
et al.39 (see Lango Allen’s Table S10) and 32 obesity-associated
genes (separated into 6 monogenic and 26 syndromic genes, i.e.,
obesity with developmental delay or dysmorphology) identified
via the OMIM database using the keywords obesity, growth, size,
and adipose tissue. The results were manually curated to identify
Stage 2 Stage 1 þ Stage 2
Variance
Explained
(%)
Frequency
(Effect
Allele) Beta (SE) p Value n I2 Phet
Frequency
(Effect
Allele) Beta (SE) p Value n I2 Phet
Low-Frequency or Rare
0.023 0.0908 (0.0129) 2.04 3 1012 134,797 0.0 1.000 0.022 0.0951 (0.0113) 3.76 3 1017 186,106 24.3 0.153 0.0787
Common
0.202 0.0257 (0.0047) 4.61 3 108 134,797 0.0 1.000 0.199 0.0302 (0.0041) 3.05 3 1013 185,169 22.9 0.172 0.0291
0.057 0.0386 (0.0082) 2.68 3 106 134,797 0.0 1.000 0.056 0.0473 (0.0072) 5.20 3 1011 180,385 18.3 0.226 0.0238
0.257 0.0176 (0.0043) 4.68 3 105 134,797 0.0 1.000 0.254 0.0238 (0.0037) 1.94 3 1010 186,106 56.2 0.001 0.0215
0.148 0.0241 (0.0053) 5.80 3 106 134,797 0.0 1.000 0.149 0.0292 (0.0046) 3.06 3 1010 178,977 0.0 0.731 0.0216
0.224 0.0185 (0.0046) 5.17 3 105 134,797 0.0 1.000 0.224 0.0232 (0.004) 5.91 3 109 180,385 31.0 0.093 0.0187
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32 genes whose variation directly leads to human obesity (Table
S7) and 15 OMIM genes with lipodystrophy morbidity (Table S8).
We then used GREAT40 to test whether variants with p value%
105 are more likely to overlap with these sets of pre-defined
genomic regions than we would expect by chance. We defined
the ‘‘regulatory domain’’ of all protein-coding genes annotated
in Ensembl release 7441 using the GREAT ‘‘basal plus extension’’
strategy: each gene is assigned a basal domain 5 kb upstream
and 1 kb downstream of the gene’s transcription start site. This
domain is then extended in both directions to the nearest gene’s
basal domain but no more than 1 Mb in either direction. We
counted the number of independent variants at the relevant
p value and MAF thresholds overlapping any of the regulatory
domains in each set of monogenic disorder-associated genes. If a
Table 2. Genome-wide Significant Independent Associations at Established Anthropometric Trait Loci
SNP Trait Chr:position Nearest Gene
Effect/
Other
Allele
Stage 1
Frequency
(Effect
Allele) Beta (SE) p Value n I2 Phet
Low-Frequency or Rare
rs62621197 height 19: 8,670,147 ADAMTS10 T/C 0.038 0.1356 (0.0202) 2.13 3 1011 47,739 0.0 0.657
rs62107261 BMI 2: 422,144 AC105393.2 C/T 0.049 0.0712 (0.0169) 2.57 3 105 47,476 29.7 0.094
rs114976626 height 19: 56,001,665 SSC5D T/C 0.029 0.1109 (0.0218) 3.87 3 107 44,180 0.0 0.691
rs183677281 height 1: 218,537,632 TGFB2 C/T 0.031 0.0993 (0.0225) 9.78 3 106 44,639 0.0 0.937
rs62038850 height 16: 2,262,987 PGP A/G 0.023 0.1046 (0.0234) 7.48 3 106 51,309 8.6 0.349
rs142854193 height 7: 33,045,510 FKBP9 T/C 0.025 0.1058 (0.0232) 5.24 3 106 51,309 0.0 0.720
Common
rs61734601 height 11: 67,184,725 PPP1CA/CARNS1 A/G 0.077 0.0877 (0.0138) 1.96 3 1010 45,588 14.1 0.282
rs41271299 height 6: 19,839,415 ID4 T/C 0.054 0.1322 (0.0157) 4.25 3 1017 51,309 51.1 0.005
rs72755233 height 15: 100,692,953 ADAMTS17 A/G 0.112 0.082 (0.0117) 2.10 3 1012 44,180 0.0 0.679
rs73175572 height 3: 185,490,184 IGF2BP2 G/A 0.125 0.0783 (0.0104) 5.62 3 1014 45,588 31.5 0.094
rs6930571 height 6: 32,383,208 BTNL2 T/G 0.166 0.0561 (0.010) 2.03 3 108 42,873 0.0 0.787
rs3888183 height 10: 121,604,702 MCMBP T/C 0.120 0.0549 (0.0104) 1.50 3 107 45,588 0.0 0.898
rs35279483 height 12: 23,996,141 SOX5 C/CA 0.401 0.0313 (0.007) 6.71 3 106 45,588 0.0 0.717
rs2003476 BMI 19: 18,806,668 CRTC1 C/T 0.400 0.0341 (0.007) 1.12 3 106 45,341 7.3 0.366
rs4360494 height 1: 38,455,891 SF3A3 G/C 0.454 0.033 (0.0069) 1.78 3 106 45,588 15.5 0.265
rs78281959 height 7: 148,772,669 ZNF786 T/C 0.065 0.0587 (0.0131) 7.55 3 106 51,309 10.3 0.327
rs62065847 waist 17: 46,593,125 HOXB1 C/T 0.487 0.0299 (0.0067) 8.15 3 106 45,996 0.0 0.523
rs13059073 height 3: 55,491,810 WNT5A C/T 0.453 0.0288 (0.0064) 6.82 3 106 51,309 0.0 0.982
rs4303473 height 16: 84,901,475 CRISPLD2 C/G 0.388 0.032 (0.0066) 1.23 3 106 51,309 0.0 0.855
rs16888802 height 4: 13,537,668 LINC01097 G/T 0.1787 0.0433 (0.0086) 4.57 3 107 51,309 24.9 0.151
rs56130800 waist 11: 43,729,853 RP11-472I20.4/ HSD17B12 A/G 0.318 0.0367 (0.0073) 4.16 3 107 44,742 0.0 1.000
rs2122823 WHR 7: 25,939,161 CTD-2227E11.1 T/C 0.209 0.0465 (0.0099) 2.66 3 106 32,507 0.0 0.789
rs1848053 height 15: 48,947,962 RP11-227D13.1 G/A 0.248 0.0385 (0.0075) 3.16 3 107 51,309 0.0 0.933
rs12591979 height 15: 89,309,892 RP11-343B18.2 C/G 0.162 0.0416 (0.0094) 9.22 3 106 45,588 0.0 0.889
rs57158761 height 3: 185,371,172 IGF2BP2 G/A 0.445 0.0301 (0.0068) 9.73 3 106 45,588 0.0 0.857
rs765876 BMI 6: 143,185,891 HIVEP2 G/A 0.476 0.0297 (0.0069) 1.52 3 105 44,092 33.1 0.086
rs2808290 height 10: 27,900,882 PPP1CA/CARNS1 T/C 0.499 0.0308 (0.0064) 1.58 3 106 51,309 12.7 0.296
rs116878242 height 17: 70,002,330 ID4 A/G 0.071 0.0688 (0.0126) 4.34 3 108 51,309 0.0 0.733
SNP positions are reported according to build 37 and their alleles are coded based on the positive strand. The reported gene is the closest in physical distance.
Association p values are based on the inverse-variance weighted meta-analysis model (fixed effects). Effect sizes are measured in standard deviation units. Abbre-
viations are as follows: BMI, body mass index; SNP, single-nucleotide polymorphism; Beta, effect size; SE, standard error; n, sample size; I2, measure of hetero-
geneity (based on Cochran’s Q-test for heterogeneity) that indicates the percentage of variance in a meta-analysis that is attributable to study heterogeneity;
Phet, p value assessing evidence of heterogeneity as reported by METAL.
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variant overlapped more than one domain, it was counted only
once. To establishwhether there is a greater than expected number
of variants overlapping the domains, we computed the proportion
of the genome covered by the regulatory domains of each gene in
the set and used this as the expected proportion of overlapping
variants under the null hypothesis. To compute the proportion
of genome covered by the gene set, we divided the total length
of the regulatory domains of all genes in the set by the total length
of the genome, excluding assembly gaps taken from the UCSC
database.42 We then tested whether the observed overlap was
greater than expected using a binomial test. We performed this
test on all independent variants (r2 < 0.2) present in the meta-
analysis results and also after excluding any previously reported
variants (5500 kb) (Figure 2). We also tested for enrichment
within different MAF categories (0.1%% MAF % 1%, 1% < MAF
% 5%, and MAF > 5%) (Figures S19 and S20).
Stage 2 Stage 1 þ Stage 2
Variance
Explained
(%)
Frequency
(Effect
Allele) Beta (SE) p Value n I2 Phet
Frequency
(Effect
Allele) Beta (SE) p Value n I2 Phet
Low-Frequency or Rare
0.042 0.1398 (0.0086) 1.87 3 1059 204,461 0.0 0.529 0.042 0.1392 (0.0079) 3.22 3 1069 252,200 0.0 0.738 0.1542
0.047 0.0763 (0.0076) 9.32 3 1024 208,397 0.0 0.461 0.047 0.0754 (0.0069) 1.27 3 1027 255,873 22.6 0.146 0.0510
0.026 0.0915 (0.0119) 1.73 3 1014 134,797 0.0 1.000 0.027 0.096 (0.0105) 5.00 3 1020 178,977 0.0 0.712 0.0479
0.026 0.0618 (0.0126) 9.80 3 107 134,797 0.0 1.000 0.027 0.0708 (0.011) 1.24 3 1010 179,436 0.0 0.885 0.0261
0.025 0.0605 (0.0127) 1.84 3 106 122,318 0.0 1.000 0.024 0.0706 (0.0112) 2.45 3 1010 173,627 15.0 0.264 0.0237
0.022 0.06 (0.0138) 1.36 3 105 134,797 0.0 1.000 0.023 0.0719 (0.0119) 1.31 3 109 186,106 0.0 0.593 0.0227
Common
0.083 0.1177 (0.0057) 1.19 3 1093 204,253 47.6 0.106 0.082 0.1133 (0.0053) 1.38 3 10101 249,841 29.5 0.088 0.1933
0.056 0.1209 (0.0077) 3.86 3 1056 175,844 0.0 0.502 0.055 0.1231 (0.0069) 1.90 3 1071 227,153 44.8 0.010 0.1583
0.112 0.0842 (0.006) 3.16 3 1045 134,635 0.0 1.000 0.112 0.0837 (0.0053) 5.42 3 1056 178,815 0.0 0.740 0.1394
0.112 0.0626 (0.0061) 8.09 3 1025 134,797 0.0 1.000 0.115 0.0666 (0.0053) 8.27 3 1037 180,385 32.1 0.084 0.0903
0.182 0.0336 (0.0049) 6.61 3 1012 134,462 0.0 1.000 0.179 0.0379 (0.0044) 6.01 3 1018 177,335 0.0 0.563 0.0422
0.118 0.0337 (0.0059) 8.86 3 109 134,797 0.0 1.000 0.118 0.0388 (0.0051) 3.29 3 1014 180,385 0.0 0.782 0.0314
0.402 0.0232 (0.0039) 1.83 3 109 134,797 0.0 1.000 0.402 0.0251 (0.0034) 1.00 3 1013 180,385 0.0 0.707 0.0303
0.406 0.0218 (0.0039) 3.31 3 108 134,509 0.0 1.000 0.404 0.0248 (0.0034) 5.89 3 1013 179,850 12.7 0.296 0.0296
0.445 0.021 (0.0038) 3.23 3 108 134,797 0.0 1.000 0.447 0.0238 (0.0033) 8.98 3 1013 180,385 19.6 0.211 0.0280
0.062 0.0439 (0.0079) 2.77 3 108 134,797 0.0 1.000 0.063 0.0478 (0.0068) 1.56 3 1012 186,106 9.6 0.334 0.0268
0.485 0.0197 (0.0039) 3.23 3 107 134,798 0.0 1.000 0.486 0.0222 (0.0033) 2.86 3 1011 180,794 0.0 0.474 0.0246
0.456 0.0192 (0.0038) 4.52 3 107 134,797 0.0 1.000 0.455 0.0217 (0.0033) 3.23 3 1011 186,106 0.0 0.967 0.0234
0.377 0.0188 (0.0039) 1.60 3 106 134,797 0.0 1.000 0.380 0.0222 (0.0034) 4.08 3 1011 186,106 0.0 0.739 0.0232
0.175 0.0231 (0.005) 3.19 3 106 134,615 0.0 1.000 0.176 0.0282 (0.0043) 5.49 3 1011 185,924 32 0.0796 0.0231
0.317 0.0191 (0.0041) 4.08 3 106 134,798 0.0 1.000 0.317 0.0234 (0.0036) 7.52 3 1011 179,540 0.0 0.976 0.0237
0.211 0.0234 (0.0048) 9.97 3 107 134,795 0.0 1.000 0.211 0.0278 (0.0043) 1.14 3 1010 167,302 0.0 0.523 0.0257
0.248 0.0194 (0.0044) 1.24 3 105 134,797 0.0 1.000 0.248 0.0243 (0.0038) 2.00 3 1010 186,106 0.0 0.747 0.0220
0.165 0.0236 (0.0052) 4.86 3 106 134,797 0.0 1.000 0.164 0.0278 (0.0045) 8.06 3 1010 180,385 0.0 0.788 0.0212
0.435 0.0174 (0.0038) 5.20 3 106 134,797 0.0 1.000 0.437 0.0205 (0.0033) 8.35 3 1010 180,385 0.0 0.756 0.0207
0.491 0.0177 (0.0039) 4.56 3 106 134,509 0.0 1.000 0.488 0.0206 (0.0034) 9.64 3 1010 178,601 35.1 0.066 0.0212
0.503 0.016 (0.0038) 2.63 3 105 134,797 0.0 1.000 0.502 0.0198 (0.0033) 1.34 3 109 186,106 22.3 0.175 0.0196
0.077 0.0224 (0.0067) 7.84 3 104 167,024 0.0 0.616 0.075 0.0326 (0.0059) 3.14 3 108 218,333 16.9 0.233 0.0148
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mQTL and eQTL Enrichment
Previous studies have suggested links between DNA methylation,
QTLs, and complex traits.43,44 We tested the hypotheses that
methylation and expression quantitative trait loci (mQTLs and
eQTLs) are enriched among anthropometric GWAS signals by
calculating fold enrichment of variants at various significance cut-
offs in the ARIES mQTL resource which comprises cis and trans
mQTLs in blood samples15 and the MuTHER-ALSPAC eQTL
resource16,17 containing cis eQTLs for LCLs, subcutaneous fat,
and skin tissue. We computed enrichments for signals using all
variants and also after excluding previously reported variants
(and variants within 500 kb) using GARFIELD.45 GARFIELD per-
forms greedy pruning of SNPs (LD r2 > 0.1) and then annotates
them based on overlap with the mQTLs. Fold enrichment (FE)
was calculated at various p value cutoffs and assessed by permuta-
tion testing, while matching for MAF, distance to nearest tran-
scription start site (TSS), and number of LD proxies (r2 > 0.8).
FE ¼ (Nat/Nt)/(Na/N), where N is the total number of pruned var-
iants, Na is the total number of annotated variants (from the
pruned set), Nt is the number of variants that pass a p value
threshold T, and Nat is the number of annotated variants at
threshold T. We calculated fold enrichments for traits only when
there were ten or more annotated variants. We used 0.05/30
(2 GWAS annotations*five time points*3 mQTL annotations) as
threshold to determine enrichment significance for mQTLs and
0.05/6 (3 tissues*2 annotations) for eQTLs.
eQTL Analysis
eQTL analysis was performed in the subset of UK10K individuals
with microarray expression profiles available from the TwinsUK
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Figure 1. Heatmap of Pairwise Genetic
Correlation Estimates between Anthro-
pometric Traits
Correlation estimates with their 95% con-
fidence intervals and 5% FDR q values
across all 66 possible pairs are given in
Table S6. Abbreviations are as follows:
BMI, body mass index; WHR, waist
to hip ratio; WaistBMIadj, waist circum-
ference adjusted for BMI; HipBMIadj,
hip circumference adjusted for BMI;
WHRBMIadj, waist to hip ratio adjusted
for BMI; TFM, total fat mass; TLM, total
lean mass; TRFM, trunk fat mass.
MuTHER study16 and ALSPAC expression
study.17 Analysis was performed with the
program PANAMA, which is based on a
probabilistic model that accounts for
confounding factors within an eQTL anal-
ysis.46 Each probe was tested for associa-
tion with all variants within 250 kb of
the gene inclusive of the gene body
and MAF R 1%. Each anthropometric
trait-associated variant was evaluated for
cis-eQTL effects by identifying associated
cis-probes and performing mutual condi-
tional analysis with the lead cis-eQTL
for the corresponding probe (Table S9).
We consider a GWAS and eQTL signal
coincident (tagging the same underlying
variant) if the eQTL p value of both the lead GWAS variant and
lead eQTL variant is >0.01 when conditioned on the opposite
SNP. In the UK10K expression dataset, 40% of genes with an
eQTL have a secondary independent cis-eQTL. We consider the
GWAS variant an independent secondary eQTL if the p value of
the association between the GWAS variant and expression when
conditioned on the lead eQTL variant still passes the FDR 1%
threshold defined for that probe. FDR thresholds were defined
via permutation at each locus.
mQTL Analysis
mQTL analysis was performed in The Accessible Resource for Inte-
grative Epigenomic Studies (ARIES). Of the 106 anthropometric
trait-associated SNPs, 97 SNPs were genotyped or successfully
imputed and passed QC (MAF > 0.001 and imputation quality
score > 0.4) in ARIES. Association analysis of SNPs with CpG sites
was performed using an additive model (rank-normalized CpG
methylation on SNP allele count) where age (excluding birth),
sex (children only), the top ten ancestry principal components,
bisulfite conversion batch, and estimated white blood cell counts
(using an algorithm based on differential methylation between
cell types)47 were fitted as covariates. We removed probes that
had a SNP at the CpG with a MAF > 0.01 in Europeans from the
1000G project and probes that mapped to multiple locations.48
We inspected the distribution of CpGs for possible effects of
a SNP at the CpG or a SNP in the probe sequence. For significant
CpGs, the lead mQTL SNP (p < 107) within 1 Mb of the
GWAS SNP was fitted as covariate to examine whether the
GWAS SNP CpG association coincided with the mQTL association
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(Table S10). We defined a mQTL as significant if the conditional
p value > 107.
Results
Association Signals
In the discovery stage across 57,129 individuals, we
observe an excess of suggestive association signals at
p % 105 (Figures S2–S14, S17, and S18, Tables S4 and
S11). We followed up these in 210,823 individuals (stage
2) of European descent (Figure S1, Tables S1 and S2).
In addition to genome-wide significant association at 187
established signals (Tables S4, S12, and S13, Figure S21),
we report 106 genome-wide significant associations with
no previous association evidence, the majority of which
are associated with human height and all of which individ-
ually have small effects (each explaining < 1% trait vari-
ance) (Tables 1, 2, and S3).
Six signals reside in genomic regions that have not been
implicated with related traits before (there are no estab-
lished positive controls for any of the 12 anthropometric
traits within 500 kb either side of the index variant; Table 1,
Figure S22), and 100 signals represent conditionally inde-
pendent associated variants at previously reported loci
(Tables 2 and S3, Figure S23). Of these 100 signals, 28 are
conditionally independent of all positive controls for any
of the traits studied (Tables 2, S14, and S15). Nine associa-
tions are at low-frequency variants. These are not captured
by the HapMap reference panel. 75 of the index variants
reside within genes, 9 are coding, and 6 are missense (Table
S16). Of the 6 variants implicating novel regions (Table 1),
2 are indels, while of 28 SNPs that are independent from
positive controls (Table 2), 1 is an indel. There are 10 indels
among the 72 variants in Table S3.
Sex-Specific Analysis
We also performed sex-specific single-point analyses
to investigate the presence of anthropometric trait signals
in males or females that are not present in the sex-com-
bined analysis. Using the same phenotype preparation
protocol, single-point and meta-analysis strategies, and
LD clumping as in sex-combined analysis, we found eight
signals in males and nine signals in females (Table S17)
that reached GWAS significance (p % 5 3 108) and are
not previously reported or identified in our sex-combined
analysis. For each of these variants and for the phenotypes
they were selected for, we computed p values testing for
difference between the meta-analyzed men-specific and
women-specific beta-estimates using a t-statistic49 and
the Spearman rank correlation coefficient across all SNPs
for each phenotype. We observe differences between sexes
for these variants at a 5% FDR (Table S17).
Rare Variant Tests
As part of the UK10K effort,7 burden tests (SKAT50
and SKAT-O51) were run separately for the ALSPAC and
TwinsUK WGS datasets, and their summary statistics
were combined using metaSKAT and metaSKAT-O52
(Figure S24). The list of regions with metaSKAT or meta-
SKAT-O p value % 105 for the anthropometric traits can
be found in Tables S3 and S10 of Walter et al.7 There are
seven regions (five non-overlapping) associated with
height, weight, total fat mass, or total lean mass with
p % 107 across either metaSKAT or metaSKAT-O results
(Table S18), but no region reached stringent genome-
wide significance. All region associations appeared to be
led by a single variant, whose signal was weakened with
the inclusion of imputed cohorts (with good imputation
quality scores). Overall, rare variant association tests ap-
peared underpowered to detect strong associations using
our combined WGS sample size (3,049–3,559) for anthro-
pometric traits.
Sample Overlap across UK-Based Cohorts
The meta-analysis method used here assumes that individ-
ual cohorts are independent from each other, i.e., samples
are not shared or related. Using raw genotypes genome-
wide, we calculated IBD estimates for the UK-based studies,
namely UK Biobank (application numbers 10205 and
7439), UKHLS (EGAD00010000918), TwinsUK WGS and
GWAS data, arcOGEN (EGAS00001001017), and 1958
Birth Cohort (we did not include ALSPAC WGS or GWAS
data, as it consists of children only). The number of over-
lapping pairs of samples (pi-hat> 0.98) between each data-
set and UK Biobank as well as related pairs (pi-hat > 0.2) is
given in Table S19. To investigate the effect of sample over-
lap and relatedness across cohorts, we focused on height
and meta-analyzed the discovery cohorts with UK Biobank
using METACARPA, a meta-analysis method that corrects
for sample overlap and relatedness across studies, as well
as METAL (which does not correct for overlap) for a direct
comparison. METACARPA was run in two stages. In the
first stage, we used genome-wide results from all cohorts
to estimate correlation across studies, and in the second
stage we meta-analyzed betas across cohorts corrected for
relatedness for the variants associated with height (Table
S20). As expected, p values uncorrected for relatedness
are inflated compared to the corrected p values but the dif-
ference is not significant (Figure S25). The correlation be-
tween the uncorrected and corrected effect sizes is almost 1
(Figure S25), and therefore the presence of any relatedness
in our data has a minimal effect on the effect sizes.
Genetic Correlation
We observe genetic correlation in 43 pairs of anthropo-
metric traits out of 66 possible pairs at 5% FDR (Figure 1,
Table S21). For example, we observe high genetic correla-
tion of BMI with weight (0.81, p < 10320), DXA traits
(0.64–0.86, p 7.14 3 1025–1.34 3 1042), waist circumfer-
ence (0.89, p< 10320), hip circumference (0.83, p¼ 8.703
10119), and waist to hip ratio (0.43, p ¼ 2.98 3 106). In
contrast, genetic correlation was not significant between
BMI and traits adjusted for BMI, such as height, waist
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Figure 2. Enrichment of Discovery Meta-analysis Results in Mendelian Height-, Monogenic Obesity-, Syndromic Obesity-, and Men-
delian Lipodystrophy-Associated Genes
We used independent variants (r2 < 0.2) with MAFR 0.1% (left) and after excluding previously reported loci (5500 kb) (right). Shown
are Mendelian height (A and B), monogenic obesity (C and D), syndromic obesity (E and F), and Mendelian lipodystrophy (G and H).
Enrichment of signal is observed if the p value (one-sided) from the binomial test of the observed versus the expected number of variants
(legend continued on next page)
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circumference, hip circumference, and waist to hip ratio
adjusted for BMI. Overall, we observe that when trait A
is positively correlated with traits B and C, the correlation
between trait A and trait B adjusted for trait C drops signif-
icantly, for example hip versus waist circumference and hip
versus waist circumference adjusted for BMI.
We also observe high genetic correlation of height with
weight (0.53, p ¼ 5.77 3 1055), hip (0.37, p ¼ 2.30 3
1013) and waist circumference (0.28, p ¼ 1.62 3 109),
as well as total fat mass (0.25, p¼ 5.213 104) and trunk
fat mass (0.23, p¼ 3.053 103) at 5% FDR.When adjust-
ing hip and waist circumference for BMI, their statistical
correlation with height becomes more significant (0.84,
p¼ 1.323 1067 and 0.73, p¼ 1.113 1051, respectively),
which implies that height could play a mediating role
in the genetic associations of these traits through its in-
verse relationship to BMI. More generally, when trait A is
positively correlated with trait B and negatively correlated
with trait C, the correlation between trait A and trait B
adjusted for trait C (or trait D positively correlated with
trait C) increases significantly. These findings are compat-
ible with previous work53 suggesting that unintended
bias, known as collider bias, can be introduced when a trait
is adjusted for another trait.
Total fat mass is highly correlated with trunk fat mass
(0.95, p ¼ 3.11 3 1079), but total lean mass is not
correlated to either of these traits. DXA traits are highly
correlated with BMI, weight, waist circumference, and
hip circumference. Compatible with the observations
above, the strongest correlations of DXA traits are with
BMI, implying a mediator role of height. Also, as expected,
the correlation between DXA traits and waist and hip
circumference disappears when the latter traits are
adjusted for BMI.
The pleiotropy among anthropometric traits is recapitu-
lated by examining the overlap of all 106 signals (Tables
1, 2, and S3) robustly associated with an anthropometric
trait at p % 5 3 108 in stage1þstage2 (Table S15) with
each of the other anthropometric traits studied. As ex-
pected, we observe significant overlap of variants associ-
ated with both weight and height (49, Figure S26A), while
11/13 variants associated with BMI are also associated
with weight (Figure S26A) and both total fat mass signals
are also trunk fat mass and BMI signals (Figure S26B).
Furthermore, 8/13 BMI signals are associated with waist
and hip circumference (Figure S26C), but this overlap
disappears once waist and hip circumference analyses
are adjusted for BMI (Figure S26E). 25/35 hip circumfer-
ence signals are also height signals (Figure S26D). Again,
we confirm systematic relationships between waist and
hip circumference signals adjusted for BMI with height
variants, as 22/23 and 52/53 of those, respectively, are
also height signals (Figure S26F).
Collider Bias
Collider bias can be introduced when a trait is adjusted for
another trait,53 for example when adjusting waist to hip ra-
tio for BMI or DXA traits for height. To investigate whether
false phenotype-genotype associations are induced when
the phenotype of interest is adjusted for another pheno-
type, we initially looked at the effect sizes in our discovery
meta-analysis for waist circumference adjusted for BMI and
BMI. Out of 146 independent (pairwise r2< 0.2 and further
than 500 kb) variants associated with waist circumference
adjusted for BMI in the discovery meta-analysis with
p < 105, 77 (52.74%) had opposite direction of effects
for BMI and waist circumference adjusted for BMI, and
therefore there was no evidence of enrichment for SNPs
harboring opposite marginal effects on the two traits
(binomial p ¼ 0.28). The expected proportion of SNPs
having effect in opposite direction in a model where the
genetic variant is associated with the outcome but not
the covariate is smaller or equal to 50%,53 which is what
we observed in our results, indicating absence of collider
bias. We observed similar results for the effect of BMI on
hip circumference and waist to hip ratio adjusted for
BMI, as well as height on DXA traits (Table S21,
Figure S27). Moreover, variants that reached genome-
wide significance for waist or hip circumference and for
waist to hip ratio adjusted for BMI are not significantly
associated with BMI (their discoverymeta-analysis p values
are between 0.85 and 0.01, while their overall p value
ranged between 0.96 and 2.64 3 104, Table S15). The
two variants associated with total and trunk fat mass
reached genome-wide significance for height but also for
BMI (Table S15), which suggests true association with
adiposity rather than mediation through height. We
concluded that there is no evidence that our results suffer
from collider bias.
Fine-Mapping
To examine the fine-mapping potential of deep WGS
imputation, we undertook fine mapping28 of the 106 asso-
ciations reported here. By combining variants predicted to
be causal with posterior probability of association over 0.1
by either CAVIARBF or PRFScore, we find that out of 30 re-
gions that successfully produced 95% credible intervals,
14 credible sets narrowed down to a single variant, 12 nar-
rowed down to 2 or 3 variants, and 3 sets were reduced
down to 4 variants (Tables S5 and S22). To assess the overall
evidence supporting functional and causal interpretation
at the 30 fine-mapped regions, we combined information
with p% 105 in Mendelian-associated genes (as calculated by GREAT and denoted by the red dot) is less than 0.05/4.482 (5% signif-
icance level Bonferroni corrected for the effective number of independent traits; horizontal red line). Observed and expected counts,
Bonferroni corrected p values, and FDR q values are given in Table S24. Abbreviations are as follows: BMI, body mass index; WHR, waist
to hip ratio; WaistBMIadj, waist circumference adjusted for BMI; HipBMIadj, hip circumference adjusted for BMI; WHRBMIadj, waist to
hip ratio adjusted for BMI; TFM, total fat mass; TLM, total lean mass; TRFM, trunk fat mass.
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from the two fine-mapping methods, two functional pre-
diction scores (Genome Wide Annotation of Variants54
[GWAVA] and GERP scores), and eQTL analysis (Figures 3
and S28). Of the 30 regions, 6 were fine-mapped to a cod-
ing variant (5 missense and 1 synonymous) and 9 were
fine-mapped to a variant that was identified as an eQTL.
Two missense variants predicted to be causal are associ-
ated with height and reside in genes of the ADAMTS family
of extracellular matrix proteases, which have been previ-
ously associated with height.39,55,56 rs72755233 (weighted
effect allele frequency [WEAF] 11.2%, beta ¼ 0.0837,
p ¼ 5.42 3 1056) resides in ADAMTS17 and causes a
non-conservative threonine to isoleucine amino acid
change in the protease domain of this peptidase. Similarly,
rs62621197 (WEAF 4.2%, beta¼0.139, p¼ 3.223 1069)
resides in ADAMTS10, null mutations in which are impli-
cated inWeill-Marchesani syndrome, characterizedby short
stature.57 Previously reported, independent variants associ-
atedwithheight at this locus reside upstreamofADAMTS10
(rs40729106) and in intronic sequence (rs724909455)
A
B
Figure 3. Combined Information from Fine-MappingMethods, Functional Prediction Scores, and eQTL Analysis to Assess the Overall
Evidence Supporting Functional and Causal Interpretation at Fine-Mapped Regions of Newly Identified Variants
Example of fine-mapping and annotation at theADAMTS17 (left) and SSC5D (right) loci for associationwith height. LocusZoom regional
association plot shown in (A) and posterior probability (PP) statistics shown in (B) are from the fine-mapping methods CAVIARBF and
PRFScore (only variantswithPP>0.1 in eithermethods are shown); genome-wide annotationof variants (GWAVA) scores; genomic evolu-
tionary rate profiling (GERP) scores; averageGERP (in a 100 bpwindowaround each variant) scores; whether the variant is an eQTL signal;
number of cell lines in which the variant overlaps with a DNase footprints (peak calls from ENCODE); number of overlapping transcrip-
tional factor binding sites based on ENCODE and JASPARChIP-seq; number of cell lines inwhich the queried locus overlapswith aDNase
hypersensitivity site (ENCODE data, peaks from Ensembl); and Variant Effect Predictor (VEP) genic annotation. Circle sizes and colors for
all scores are scaled with respect to score type and numbers are plotted below each circle. Probabilities of causality from CAVIARBF and
PRFScore are colored in shades of purple. GWAVA scores range between [0,1] and scores greater than 0.5 indicate functionality (colored
inwhite for scores<0.5 and in shadesof orchid for scores>0.5).GERP scores rangebetween [12.3,6.17]with scores abovezero indicating
constraint (colored in white for scores < 0 and in shades of orchid for scores > 0).
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(Table S14). rs62621197, identifiedhere, results in an amino
acid substitution (p.Arg62Gln) directly adjacent to the furin
cleavage site, where the presence of glutaminemaydecrease
ADAMTS10 activation efficiency.58
We also undertook fine mapping28 of 186 anthropo-
metric trait loci established in the literature which also
reached p % 5 3 108 in the discovery stage (Table S4).
We find that 14 credible sets 95% likely to contain the
causal variant are narrowed down to a single variant, and
6 are narrowed down to 2 causal variants (Table S23).
For example, fine-mapping of the region around the
previously established variant rs28929474 resulted in a
credible set of two missense variants associated with
height. rs28929474 (WEAF 2.1%, beta ¼ 0.138, height
p ¼ 5.35 3 1041) in SERPINA1 encodes a missense change
(p.Glu366Lys) in the serine protease inhibitor domain of
alpha-1-antitrypsin (AAT). Homozygosity results in AAT
deficiency, associated with increased risk of early-onset
chronic obstructive pulmonary disease.59 rs28929474 het-
erozygosity has been associated with increased pulmonary
function and height.60 AAT inhibits cleavage of the reac-
tive center loop of corticosteroid binding globulin (CBG)
(coded by SERPINA6, located next to SERPINA1), prevent-
ing the release of cortisol. Variation in this locus has
been associated with plasma cortisol levels61 and there is
epidemiological evidence that cortisol and height are
inversely correlated.62
Enrichment of Association Signal in Monogenic and
Syndromic Disorder-Associated Genes
Consistent with previous work,4,6,63 we find enrichment
of height-associated signals in genes mutated in human
syndromes characterized by abnormal skeletal growth
(2.51-fold enrichment; p ¼ 3.38 3 108), of BMI-related
signals in genes implicated in monogenic obesity (19.32-
fold enrichment for BMI; p ¼ 5.43 3 104) and of total
lean mass-related associations in Mendelian lipodystro-
phy-associated genes (52.86-fold enrichment for BMI;
p¼ 6.903 104) (Figure 2, Table S24). Enrichment remains
after the removal of established lipodystrophy loci and is
attenuated when previously identified height and BMI
common-frequency variant signals are removed (Figures
2, S19, and S20, Table S24).
We also observe enrichment of BMI-, weight-, waist-, and
height-related signals in monogenic obesity-related genes
(Figures 2 and S20), which can be explained by the fact
that these phenotypes are highly correlated (Figure 1). The
absence of enrichment of hip circumference, waist to hip
ratio, and DXA-related signals (despite their significant cor-
relation to BMI, estimated using genome-wide estimates in-
dependent of p value thresholds) is likely due to low power
to detect enough signals with p< 105 (their sample sizes in
our discovery phase are approximately 37K and 15K).
Proximity to OMIM Genes
We examined whether any genes with an associated
OMIM morbidity identifier were located within 1 Mb of
the identified variants, andwe found 268 such genes across
103 out of the 106 signals (Table S25). Among these genes
many were implicated in bone development and musculo-
skeletal phenotypes. One gene (ADAMTS10) was overlap-
ping with an identified signal for height (index variant
rs62621197) and it is involved in Weill-Marchesani syn-
drome (MIM: 277600), a connective tissue disorder charac-
terized by short stature.57 Other genes and their implicated
roles are summarized in Table S25. Pathogenic mutations
associated with these OMIM genes were not in LD with
our reported signal (r2 is 0) and were not present in the
UK10K WGS dataset.
Musculoskeletal Phenotypes
Consistent with previous work,5,6 we observe a strong
theme ofmusculoskeletal implications (79 of 106 variants).
A variant was considered to have musculoskeletal implica-
tions if (1) it is located within 100 kb or if it is an eQTL for
a gene that has a relevant OMIM annotation, including
association with human syndromes and animal models of
relevant gene knock-outs,64–83 such as abnormal skeletal,
muscle, or cartilage development and abnormal body
size or bone morphology, and (2) there are any skeletal-
related GWAS signals within 100 kb, such as bone mineral
density. For example, rs35863206 (WEAF 22.35%, beta ¼
0.0232, height p ¼ 5.91 3 109) is a deletion located
53 kb upstream of PGR, which encodes the progesterone
receptor protein and is correlated with rs147581469 (r2 ¼
0.72), a previously identified eQTL for PGR.84 Pgr mouse
knock-out models exhibit severe abnormal ossification
and skeletal irregularities.67
eQTL Analysis Results
We find cis eQTL enrichment (p < 0.008, Table S26) for
BMI, height, weight, waist circumference, and waist to
hip ratio adjusted for BMI signals in subcutaneous fat
and for BMI, height, weight, and waist circumference in
lymphoblastoid cell lines (Table S26). BMI and height
show the strongest enrichments at multiple GWAS thresh-
olds. No significant eQTL enrichments are found for
waist to hip ratio, hip circumference, hip circumference
adjusted for BMI, total fat mass, total lean mass, or trunk
fat mass. Overall, no enrichments are found for skin
eQTLs. After excluding regions of previously identified
loci, the enrichment remains significant for height and
waist circumference adjusted for BMI in subcutaneous fat
and for all traits in LCLs. Subcutaneous fat eQTLs is en-
riched among height and waist circumference adjusted
for BMI GWAS signals. GWAS signals show enrichments
at GWAS thresholds of 105 and 106. Given that the
LCL sample size is twice as that of the other two tissues
(n ¼ 823 in LCLs, n ¼ 391 adipose tissue, n ¼ 367 skin tis-
sue) and that the expression data of a transformed cell line
is less prone to environmental effects, the number of
eQTLs for LCLs is larger than for fat and skin, which
may explain the larger number of LCL eQTLs enrichments
among anthropometric traits.
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To integrate the identified variants with the eQTL data,
reciprocal conditional analyses were performed in the
expression data with the lead GWAS variant and peak
eSNP to identify coincident signals. Several of the GWAS
variants coincided with the lead eQTL for neighboring
genes, including rs3888183 forMCMBP in all three tissues,
rs4360494 for FHL3 in adipose and LCLs, rs6901225 for
ABT1 in LCLs and rs577721086 for RSPO3 in adipose
(Table S9). Additional GWAS variants were associated
with gene expression after conditioning on the lead
eQTL, indicating that they are tagging independent sec-
ondary eQTLs. We note that as some variants have low
MAF, the relatively modest size of the UK10K expression
dataset is underpowered to detect eQTLs and larger expres-
sion studies may reveal further regulatory effects associated
to these variants.
mQTL Analysis Results
Wefind signal enrichment for mQTL (p< 0.002, Table S27,
Figure S29) in blood samples at three time points in the life
course of ALSPAC participants and two time points in the
life course of their mothers15 at different p value thresh-
olds, mostly driven by cis mQTLs for BMI, height, waist
circumference, weight, total fat mass, and trunk fat mass.
After excluding previously reported variants (and all vari-
ants within 500 kb), BMI, height, waist circumference,
weight, total fat mass, and trunk fat mass variants re-
mained significantly enriched for mQTLs for several time
points. However, the total fat mass and trunk fat mass en-
richments disappeared after removing previous published
BMI and obesity GWAS signals.
Height and weight show enrichment of trans mQTLs
during pregnancy and birth, whereas BMI was not en-
riched for trans mQTLs using the same sample size in the
GWAS analysis. Enrichment of trans mQTLs is consistent
with the possibility that the relative influence of the envi-
ronment on methylation levels increases over time. Also,
given that trans mQTL signals may be polygenic them-
selves, enrichment of trans mQTLs may be explained by
the polygenic architecture of traits such as height. Overall,
stronger enrichments were found for cismQTLs than trans
mQTLs and a lower GWAS threshold resulted in stronger
enrichments. Comparing different GWAS thresholds con-
firms that among associations that do not surpass the
genome-wide significance p value threshold, functional in-
formation can enhance discovery of true associations.
These findings confirm that trait-associated SNPs will often
affect the trait by gene regulation. Using large sample sizes
leads to higher power to detect enrichment for complex
polygenic traits, such as the anthropometric traits studied
here.
Of the 97 reported variants tested in ARIES, 76 variants
showed evidence for mQTL (664 unique SNP-CpG pairs
across all time-points, p < 107) of which 550 associations
were in cis and 114 in trans (Table S10).
Discussion
We have conducted a sequence-based association scan
for anthropometric traits empowered by deep imputation
(Figures S30 and S31). A keymessage derived from our find-
ings is that large-scale, well-imputed association scans
continue to discover complex trait loci. As an exemplifica-
tion of the point, we identify associations at low-fre-
quency variants, not captured by previous reference
panels, including a large number of associations at com-
mon-frequency variants, which were missed by previous
studies.4–6,85 These are signals for traits not studied exten-
sively before (n ¼ 40/97 in Table S3) but are genetically
correlated to other well-studied anthropometric traits,
not tagged by previous imputation approaches (n ¼ 7/28
in Table 2, n ¼ 16/97 in Table S3), or reaching sub-
threshold significance levels in previous studies (n ¼ 21/
28 in Table 2, n ¼ 41/97 in Table S3). Therefore, further
increasing sample size and sequencing depth and building
large reference panels to facilitate accurate imputation is
likely to identify further potentially functional variants
underpinning the genetic architecture of medically rele-
vant human complex traits. Transethnic fine-mapping of
deeply imputed datasets can then deliver further resolu-
tion of causal genes and variants.86
We found moderate overlap of genes implicated by the
GWAS, the two fine-mapping methods, and eQTL and
mQTL analyses (Table 3). Altogether we have found 283
unique genes, 225 (79.5%) of which were found by only
one method, while there were no genes identified by all
methods (46 and 12 genes were found by two or three
methods, respectively). Out of 99 genes identified by the
GWAS, 13 were identified by fine-mapping, 8 by eQTL,
and 41 by mQTL. The observed moderate overlap across
analysis strands suggests that the closest protein-coding
gene to a susceptibility variant is not necessarily the gene
affected by the variant, or that indeed the variant does
not affect gene methylation or expression. Out of these
13 genes that were identified by both GWAS and fine
mapping, 12 (CDK6, IGF2BP2, HSD17B12, ID4, ZBTB38,
ADAMTS10, RSPO3, MAPK3, DLEU1, ADAMTS17, GDF5,
Table 3. Pairwise Overlap of Genes Implicated by the GWAS, Two
Fine-Mapping Methods, eQTL and mQTL Analyses
GWAS
Fine-
Mapping eQTL mQTL
Total
Genes
Unique
Genes
GWAS 99 13 8 41 99 49 (49.5%)
Fine-
mapping
13 24 2 9 24 8 (33.3%)
eQTL 8 2 19 9 19 6 (31.6%)
mQTL 41 9 9 211 211 162 (76.8%)
283 225 (79.5%)
Closest protein-coding genes identified by the GWAS and the two fine-map-
ping methods CAVIARBF and PRFScore, and genes identified by the eQTL
and mQTL analyses.
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and PDXDC1) have been previously associated with
anthropometric GWAS signals.
To get a functional overview of the genes implicated by
the different methods, we classified them based on their
associated gene ontology (GO) terms for biological pro-
cesses. Before the analysis, GO gene sets were filtered to
keep the most reliable associations, namely only those
genes were kept in a biological process group, where the
supporting evidence was: physical interaction, mutant
phenotype, direct assay, expression pattern, or traceable
author statement. The final set contained 9,440 genes
distributed across 2,833 overlapping categories. Our 283
identified genes were assigned 377 different annotation
terms (Table S28). Focusing on 52 annotation terms that
contained three or more genes, the most pronounced cat-
egories were related to gene regulation, immune system,
signal transduction, and cell proliferation. Other high-
lighted processes were related to metabolism and develop-
ment terms, as well as skeletal system development repre-
sented by five genes (SOX9, BMP2, IGFBP4, NKX3-2, and
FBN1) (Table S28).
The gene sets associated with methylation and expres-
sion QTLs yielded 64 different gene ontology annotations
with at least two ormore genes (Table S29). Themost abun-
dant categories were related to immune system, cell prolif-
eration, and gene expression, and there were also ontology
terms with clear musculoskeletal consequences, such as
skeletal system development, chondrocyte differentiation,
and regulation of ossification. These annotations were rep-
resented by genes previously identified from genome-wide
association studies of anthropometric traits, such as CDK6,
GDF5, HMGA2, IGFBP4, FBN1, and WNT5A, which sug-
gests that eQTL and mQTL analyses can contribute to
our understanding of the biology underlying complex
traits but were also represented by three genes (PDK1,
NKX3-2, VPS29) with no previously reported GWAS associ-
ations. Looking closely into these genes, we found animal
models and other biological information supporting their
relevance to anthropometric traits.
Specifically, PDK1 is the closest protein-coding gene to
rs28610092, associated with waist circumference adjusted
for BMI in our study, was implicated by fine-mapping,
and is a mQTL. Animal models of PDK1 show abnormal
adipose tissue development87 and a series of skeletal and
ossification abnormalities including abnormal radius88
and femur87 morphology, as well as abnormal osteoblast
differentiation.87 NKX3-2 is a homeobox gene and the
closest protein coding gene to rs16888802, associated
with height in our study, and identified by the GWAS
and mQTL analyses. Although NKX3-2 has no previous
anthropometric associations, it is associated with spon-
dylo-megaepiphyseal-metaphyseal dysplasia, an auto-
somal-recessive disorder characterized by diverse skeletal
abnormalities,72 including disproportionate short stature
with a short and stiff neck and trunk.72 These phenotypic
abnormalities were recapitulated in mouse models.89–91
Figure 4. Power to Detect Association in
the Discovery Stage, Stage 1
Effect sizes and 95% confidence intervals
(absolute value of beta, expressed in stan-
darddeviationunits) as a functionofminor
allele frequencies (MAF), based on stage 1
of this study. Newly reported variants are
denoted in diamonds, and previously re-
ported variants that reach genome-wide
significance (p % 5 3 108, two-sided) in
the discovery stage are denoted in circles.
The curves indicate 80% power at the
genome-wide significance threshold of
p%53108, for five representative sample
sizes of the discovery stage: (1) height,
BMI, weight; (2) TFM, TLM; (3) TRFM; (4)
waist circumference, waist circumference
adjusted for BMI; (5) hip circumference,
waist to hip ratio, hip circumference
adjusted for BMI,waist tohip ratio adjusted
for BMI. The sample size for height (blue
line) had 80% power to detect associations
down to 0.1% MAF for betasR 0.19 stan-
dard deviations (0.36 and 0.23 for TFM
[orange] and waist to hip ratio [purple],
respectively; not plotted). Further power
calculations for different sample sizes are
given in Figure S32. Abbreviations are as
follows: BMI, bodymass index;WHR,waist
to hip ratio; WaistBMIadj, waist circum-
ference adjusted for BMI; HipBMIadj,
hip circumference adjusted for BMI;
WHRBMIadj, waist to hip ratio adjusted
for BMI; TFM, total fat mass; TLM, total
lean mass; TRFM, trunk fat mass.
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Finally, VPS29 was associated to the weight signal
rs112540634 by mQTL analysis. The protein product of
VPS29 is part of the retromer complex of theWnt signaling
pathway,92,93 which is involved in adipogenesis and adipo-
cyte development.94,95
The pronounced representation of immune-related an-
notations in the gene sets identified by eQTL and mQTL
might be explained by the blood-related sources of the
studied tissues (mQTL data come explicitly from blood;
LCLs, subcutaneous fat, and skin tissues were used for
the eQTL data, but the LCL sample size is twice as that of
the other two tissues).
In this study, we set out to identify associations across
the full allele frequency spectrum. Consistent with previ-
ous studies,96–98 we find substantial genetic overlap be-
tween monogenic and polygenic anthropometric traits,
driven primarily by common variants with small effect
sizes. Importantly, even though well powered to detect
them, we find no evidence of low-frequency variants
with strong effect sizes (Figure 4). For example, for height
and waist to hip ratio, this study had 80% power to detect
associations down to 0.1% MAF for betasR 0.19 and 0.23
standard deviations, respectively, at the genome-wide sig-
nificance level. It is possible that this picture might change
with larger sample sizes sequenced at higher read depths,
which would allow researchers to systematically interro-
gate variants with MAF < 0.1% and increase association
power for small effect sizes for low frequency and rare
variants. Millions of variants with MAF < 0.1% were not
included in this study, many due to imputation accuracy
score filters. There may therefore still be true signal to
discover in the 0.1%–1% MAF range—even with current
sample sizes—if the imputation qualities improve. In addi-
tion, within the power constraints of the study, we do not
identify any significant association with burdens of rare
variants. It is likely that such burdens exist but that the
rare variants contributing to them could not be detected
by the low read depth of the WGS data generated here.
Going forward, deep whole-genome sequencing of large-
scale cohorts holds the promise of comprehensively inter-
rogating the allelic architecture of complex traits.
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